[PDF] Top 20 Valorización de Volcan Compañía Minera S.A.A.
Has 10000 "Valorización de Volcan Compañía Minera S.A.A." found on our website. Below are the top 20 most common "Valorización de Volcan Compañía Minera S.A.A.".
Treatment and management of myelofibrosis in the era of JAK inhibitors
... for treatment of splenomegaly, and management of anemia with transfusions, erythropoiesis-stimulating agents (ESAs), androgens, and immunomodulatory agents ... See full document
11
Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
... the treatment effects, and heterogeneity resulting from inclusion of studies from several different ...one treatment over another in patients using ... See full document
10
Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection
... grase inhibitors, in addition to other new drugs that attack different targets such as entry and viral maturation, could possibly be used to create even more potent drug regimens that we use ...integrase ... See full document
40
JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
... kinase inhibitors have been developed, including a variety of JAK kinase inhibitors (Table ...these inhibitors are still under development, the JAK1/ JAK2-selective inhibitor ruxolitinib is ... See full document
22
Ipilimumab in the treatment of metastatic melanoma: management of adverse events
... The evidence that ipilimumab significantly improves OS in advanced melanoma patients has led to its approval for the treatment of pretreated metastatic melanoma. Ipilimumab, which inhibits CTLA-4, activates and ... See full document
15
Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1
... world. Treatment-experienced adults with virologic fail- ure on stable antiretroviral therapy, documented NNRTI genotypic resistance, viral load over 5000 copies/mL, and 3 or more primary PI mutations were ... See full document
6
Front line treatment of elderly multiple myeloma in the era of novel agents
... personalized treatment approaches, based on patient comorbidities, as the three novel agents have somewhat different toxicity profi ...maintenance treatment needs to be further inves- ...effective ... See full document
61
Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer
... the management of patients with NSCLC are beneficial to only a small percentage of patients (approximately 10% and 4% of total patients with NSCLC of Caucasian origin have alterations in EGFR and anaplastic ... See full document
43
Role of 5 alpha-reductase inhibitors in the management of prostate cancer
... The PCPT was a multicenter, randomized, double blind, placebo-controlled clinical trial comparing finasteride with placebo in the prevention of adenocarcinoma of the prostate. 18 882 men over the age of 55, with a PSA of ... See full document
23
BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects
... Small-molecule inhibitors, such as JQ1 and i-BeT151, compete with the acetyl-binding pockets present in the bromodomains of BeT proteins and block BeT-dependent gene ... See full document
35
Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer
... improving treatment options for ...or treatment, as well as a worse overall outcome on standard therapies, the targeted development path becomes imperative for cancer patient ... See full document
23
The role of antipsychotics and mood stabilizers in the treatment of bipolar disorder
... antipsychotic treatment trials in bi- polar disorder have confirmed that atypical antipsychotic monotherapy is superior to placebo regarding an acute manic and mixed ...the treatment and prevention of ... See full document
13
Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes
... optimal treatment should be continuation of the same mTOR inhibitor or if another drug targeting the PI3K-AKT-mTOR pathway should be administered in addition to a modified endocrine ... See full document
106
Long-term safety of aromatase inhibitors in the treatment of breast cancer
... When prospectively assessed, vaginal bleeding was sig- nifi cantly less frequent with anastrozole than tamoxifen in the ATAC study (5.4% vs 10.2%; p 0.0001), as with letrozole in the BIG 1–98 trial (3.8% vs 8.3%; p ... See full document
7
Current and emerging treatment options in the management of Friedreich ataxia
... may silence frataxin expression inducing heterochromatin formation, and/or forming non B-DNA structures, such as triplex and sticky DNA, which block gene transcription. Therefore, possible treatments for FRDA may include ... See full document
158
Current and emerging treatment options in the management of lupus
... therapeutic management of SLE is the longstanding overreliance on corticosteroid therapy which contributes substantially to damage accrual and patient ...the management of SLE with a discussion of recent ... See full document
12
MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
... The results of combination therapy of MEK inhibitors and BRAF inhibitors are promising. New clinical trials confirm improved PFS with concurrent inhibition of BRAF and MEK. coBRIM (NCT01689519), a Phase ... See full document
12
Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies
... Pseudo-progression is a clinical challenge for practi- tioners and patients. When patients are informed regarding potential pseudo-progression, they may continue treatment in the presence of tumor enlargement or ... See full document
29
LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
... Another interesting prospect is whether LRRK2 inhibi- tors could also be used to treat more common idiopathic PD. Potential mediators of LRRK2 pathobiology, including lysosomal clearance defects, inflammation, and ... See full document
10
Potential role of aromatase inhibitors in the treatment of endometriosis
... A PubMed search was carried out to identify all the pub- lished studies evaluating the efficacy of AIs in treating endometriosis-associated pain and endometriosis-associated infertility with the following keywords: ... See full document
11
Related subjects